monocyte-derived TNF-α may exert direct effects on pyramidal neurons, but it is unclear how the cytokine reaches the brain parenchyma. Moreover, the poly(I:C)-induced increase of TNF-α in the cerebral cortex is only transient, such that local neurons 5 or glia may be required to sustain the effects beyond 24 h. One potential mechanism for the production of a lasting response to systemic infection is that astroglia (Fig. 1) might be stimulated to release brain-derived neurotrophic factor, which is an important factor for learning-dependent synaptic remodeling. Indeed, reactive astrocytes were observed in the primary motor cortex within 24 h after systemic poly(I:C) challenge 5 .
Finally, endothelial cells ( Fig. 1) could have a crucial role. In fact, virus-induced sickness behavior was recently found to be induced by interferon-receptor chain 1 engagement on brain endothelial cells in the absence of BBB disruption in mice 12 .
Despite the need for future discoveries, the study by Garré et al. 5 provides fascinating new insights into the role of patrolling monocytes in sickness behavior. The current work opens up the possibility of new therapeutic interventions that specifically target TNF-α in circulating monocytes. Ultimately, these interventions might also play a part in the treatment of neurodegenerative diseases.
The cannabis paradox: when age matters

Andrés Ozaita & Ester Aso
New evidence in mouse models reveals that exposure to Δ 9 -tetrahydrocannabinol (THC), the main psychoactive component in Cannabis sativa, might improve cognitive performance in aging animals. 1 and Europe 2 , 7.5% and 10%, respectively, are estimated to use cannabis. Phytocannabinoids, found in cannabis, modulate the endogenous cannabinoid system by supplanting the endogenous cannabinoids (endocannabinoids). This is a neuromodulatory system composed of receptors, endocannabinoids and the enzymes involved in their synthesis and degradation, and it regulates a range of physiological functions, including learning and memory 3 . The main cannabinoid receptor in the brain is the CB1 receptor, which is responsible for most of the central effects of THC 4 . In this issue, Bilkei-Gorzo et al. 5 reveal the divergent effects of long-term exposure to a relatively low dose of psychoactive cannabinoid THC 6 on the cognitive performance of mice of different ages (Fig. 1) . They attribute these effects to signaling through CB1.
The authors first show that THC exposure in mature and old mice (12 and 18 months, respectively) restored cognitive function to a level similar to that in young untreated mice. By contrast, they found in young adult mice (2 months old), by using a variety of learning and memory tests, that THC exposure has a deleterious effect on cognition, a finding that is in agreement with other studies 7 .
The authors then investigated the mechanisms involved in the paradoxical effects of THC, focusing on the hippocampus, a brain region intimately linked to cognitive performance. They found that synaptic density in this brain region, inferred from the expression of synaptic proteins in the hippocampus, dropped in aged mice as compared to young mice, but that after chronic THC treatment, expression levels were restored to levels resembling those in young mice. Furthermore, they found that the gene expression profile of the hippocampus of THC-treated mature mice resembled vehicle-treated young mice, and that the profile of THC-treated young mice was similar to vehicle-treated mature mice. Among the many genes differentially expressed, the authors pinpointed klotho, transthyretin and brain-derived neurotrophic factor (BDNF) as being upregulated in THC-treated mature mice, as compared to those in untreated mice; all of these genes are linked to life span, cognitive modulation and synaptic plasticity. By contrast, the two most strongly downregulated genes observed in THC-treated mature mice-connective tissue growth factor and caspase 1-regulate pro-aging processes. Thus, the authors' data suggest that these genes sustain the cognitive improvement observed in THC-treated mature animals.
The authors were then able to identify a potential mechanism that might mediate the effects on cognition of THC treatment in aging mice. In these mice, they identify enhanced phosphorylation of hippocampal signaling pathways that are relevant for learning and memory, such as cAMP-response elementbinding protein (CREB) and extracellularsignal-regulated kinase (ERK), as compared to untreated mice. In addition, these older, treated mice had enhanced histone acetylation in the hippocampus, an epigenetic modification that is linked to active gene transcription. Enhanced acetylation was found in the klotho and BDNF promoters in THC-treated mature mice. Further proof for a role for this histone acetylation in the effects of THC treatment on synaptic density in aged mice came from the concomitant administration of an acetyl-transferase inhibitor during THC exposure. The use of this combination on aged mice resulted in no change in cognitive ability, expression of synaptic markers, acetylation of histones, or volume 23 | number 6 | june 2017 nature medicine potentially related to the mechanism described by Bilkei-Gorzo et al. 5 .
The second question raised by this study has to do with the drug used. THC activates CB1 receptors, but also other not-so-abundant cannabinoid receptors. According to the present study, the use of more selective drugs than the phytocannabinoid THC should show effects similar to those described by Bilkei-Gorzo et al. 5 . Conversely, and in relation to this second question, would C. sativa preparations be as beneficial as THC? THC is one of at least 85 cannabinoids present in cannabis preparations. Such a complex blend of cannabinoids with diverse activities throughout the organism (some complementary, but others antagonistic or even independent from those of THC), combined with their varied relative abundance in the diverse cannabis plant strains and preparations, are rarely well controlled. Therefore, such considerations will have to be addressed in future studies to understand whether cannabis preparations are suitable, and they will be necessary for individuals to obtain medical-grade products that could benefit from the mechanisms described by Bilkei-Gorzo et al. 5 .
Considering the increase in human life span worldwide, the promotion of healthy aging is currently a priority, as well as an economic and social challenge. The study by Bilkei-Gorzo et al. 5 opens the door to a potentially novel approach for combatting the cognitive consequences of aging by using THC. Only complementary clinical studies will reveal whether we may benefit from those effects found in aging mice.
several deleterious processes, such as neuroinflammation, oxidative stress, mitochondrial disarray and impairments to the degradation of aberrant molecules, converge in the brain 8 . This triggers a loss of neural plasticity and function, which, in the absence of proper cell turnover, can lead to cognitive decline. Thus, as in mice, THC could in humans target specifically those degenerative events occurring in the aging brain, and so lead to a different response in young and healthy individuals. In agreement with this idea, recent evidence shows that a repeated low dose of THC improves cognitive performance in a mouse model of neurodegenerative disease, whereas it induces memory impairment in healthy mice 9 , and that direct klotho expression enhancement improves cognitive performance in a mouse model of Alzheimer's 10 -findings that are all in the expression of klotho and BDNF relative to the same factors in untreated aged mice. Importantly, mature mice lacking the CB1 receptor in the main forebrain glutamatergic neurons did not show any of the benefits of THC treatment in the parameters studied.
The present study supports a valuable and unexpected effect of THC in elderly, as compared to young adults, but it also opens up the debate on a number of issues. First, the study raises the question of the translational relevance of the discoveries in mice. At what age, and under which circumstances, would an individual be capable of experiencing the described beneficial effects of THC? If we try to estimate a parallel in humans, such a study in a clinical setting would need to involve 3-4 years of sustained THC treatment. It should be taken into consideration that during aging, Figure 1 Bilkei-Gorzo et al. 5 show in mature and old mice (12 and 18 months old, respectively) that THC increases the density of hippocampal synapses; the phosphorylation of signaling proteins involved in learning and memory; and levels of histone acetylation in the hippocampus. It also results in an increase in cognitive performance. By contrast, THC has no such molecular effects in young mice, and its effects on cognition are detrimental. 
